Compare Nano Dimension Ltd - ADR (NNDM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Natera Inc. Common Stock — how do they compare? Nano Dimension Ltd - ADR trades at $1.39 (market cap $306.41M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 186.1× Nano Dimension Ltd - ADR's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and Natera Inc. Common Stock for 0 Days on average.
| NNDM | NTRA | |
|---|---|---|
Market Cap | $306.41M | $57.03B |
Volume | 1,735,346 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $2.14 | $425.64 |
52-Week Low | $1.21 | $179.42 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | -$98.44M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.41, down 6.62% with a bearish technical signal. The company shows revenue growth to $102.44M in 2025 but deepens net losses to -$293.30M, resulting in a negative net margin of -286.32%. Recent strategic moves include appointing a new board member and cost-saving initiatives targeting $25M in annual cash burn reduction. The stock faces significant selling pressure with 18 sell signals versus 7 buy signals in technical indicators.
The outlook remains challenging with persistent losses despite revenue growth. Investment opportunity exists in the company's cash position of $757.96M and low EV/EBITDA of 0.19, but risks include negative cash flow, leadership transitions, and shareholder activism. The stock trades near support levels with institutional sentiment cautious amid ongoing restructuring efforts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
